Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fosinopril sodium, quantity: 10 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; pregelatinised maize starch; hyprolose; crospovidone; glyceryl behenate - monace is indicated for the treatment of mild to moderate hypertension. monace is effective alone as initial therapy or in combination with other antihypertensive agents. the antihypertensive effects of monace and diuretics used concomitantly are approximately additive. data have not been provided to support the use of monace in severe or renovascular hypertension. heart failure: monace is indicated for the management of heart failure when added to conventional therapy, including diuretics.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fosinopril sodium, quantity: 20 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; crospovidone; povidone; glyceryl behenate - hypertension: treatment of mild to moderate hypertension. fosinopril is effectine alone as initial therapy or in combination with other antihypertensive agents. the antihypertensive effects of fosinopril and diuretics used concomitantly are approximately additive. data have not been provided to support the use of fosinopril in severe or renovascular hypertension. heart failure: management of heart failure when added to conventional therapy, including diuretics.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fosinopril sodium, quantity: 10 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; crospovidone; povidone; glyceryl behenate - hypertension: treatment of mild to moderate hypertension. fosinopril is effectine alone as initial therapy or in combination with other antihypertensive agents. the antihypertensive effects of fosinopril and diuretics used concomitantly are approximately additive. data have not been provided to support the use of fosinopril in severe or renovascular hypertension. heart failure: management of heart failure when added to conventional therapy, including diuretics.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - captopril, quantity: 50 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose; maize starch; stearic acid; sodium starch glycollate - hypertension. treatment of hypertension. in using zedace, consideration should be given to the risk of neutropenia/ agranulocytosis (see precautions). zedace is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the hypotensive effects of captopril and thiazides are approximately additive. myocardial infraction. zedace may be used to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, manifested as an ejection fraction less than or equal to 40%, and to decrease the incidence of overt heart failure and subsequent hospitalisations for congestive heart failure in these patients. the efficacy data for the use of captopril following myocardial infarction are strongest for commencement of therapy beyond three days postinfarction. heart failure. treatment of heart failure. it is recommended that zedace be administered together with a diuretic in symptomatic patients. diabetic nephropathy. zedace is also indicated in the treatment of diabetic nephropathy in patients with type i insulin- dependent diabetes mellitus.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - captopril, quantity: 25 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose; maize starch; stearic acid; sodium starch glycollate - hypertension. treatment of hypertension. in using zedace, consideration should be given to the risk of neutropenia/ agranulocytosis (see precautions). zedace is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the hypotensive effects of captopril and thiazides are approximately additive. myocardial infraction. zedace may be used to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, manifested as an ejection fraction less than or equal to 40%, and to decrease the incidence of overt heart failure and subsequent hospitalisations for congestive heart failure in these patients. the efficacy data for the use of captopril following myocardial infarction are strongest for commencement of therapy beyond three days postinfarction. heart failure. treatment of heart failure. it is recommended that zedace be administered together with a diuretic in symptomatic patients. diabetic nephropathy. zedace is also indicated in the treatment of diabetic nephropathy in patients with type i insulin- dependent diabetes mellitus.

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - fosinopril sodium, quantity: 10 mg - tablet, uncoated - excipient ingredients: crospovidone; sodium stearylfumarate; lactose; povidone; microcrystalline cellulose - hypertension: monopril is indicated in the treatment of mild to moderate hypertension. monopril is effective alone as initial therapy or in combination with other antihypertensive agents. the antihypertensive effects of monopril and diuretics used concomitantly are approximately additive. data have not been provided to support the use of monopril in severe or renovascular hypertension. heart failure: monopril is indicated for the management of heart failure when added to conventional therapy, including diuretics.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amiloride hydrochloride dihydrate, quantity: 5 mg - tablet, uncoated - excipient ingredients: maize starch; povidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate - indications as at 15 july 1998 : kaluril's main indication is as concomitant therapy with diuretics to conserve potassium during periods of vigorous diuresis and during long-term maintenance therapy with thiazides or other more potent diuretics. kaluril when used alone, has mild diuretic and antihypertensive activity. oedema of cardiac origin. although kaluril alone may provide adequate diuresis for some patients with oedema of cardiac origin, it is primarily indicated for concomitant use in patients receiving thiazides or more potent saluretic diuretic agents. in these patients it may provide increased sodium, chloride and water excretion and decreased potassium excretion. the positive effect of kaluril on potassium balance may be especially important for digitalised cardiac patients, in whom potassium depletion sensitises or exaggerates the response of the heart to the toxic effects of digitalis (e.g. increased ventricular irritability), which may precipitate digitalis intoxication with potentially seriou

Ireland - English - HPRA (Health Products Regulatory Authority)

merck sharp and dohme limited - amiloride hydrochloride hydrochlorothiazide - tablets

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme (uk) ltd - amiloride hydrochloride; hydrochlorothiazide - oral tablet - 5mg ; 50mg

Canada - English - Health Canada

teva canada limited - amiloride hydrochloride; hydrochlorothiazide - tablet - 5mg; 50mg - amiloride hydrochloride 5mg; hydrochlorothiazide 50mg - potassium-sparing diuretics